Palisade BioPalisade Bio terminates its post-surgical abdominal adhesions treatment trial

Preview

来源: Pharmaceutical Technology

Phalguni Deswal

@Phalguni_GD

Preview

来源: Pharmaceutical Technology

Tranexamic acid is also under development for post-operative ileus, and accelerating the return of bowel function post-abdominal surgery. Image Credit: Buravleva stock / Shutterstock.

Palisade Bio has terminated the development of its lead clinical candidate, tranexamic acid (LB1148), for reducing intra-abdominal adhesions in patients after elective bowel resection surgery.

The news led to a sharp 69% decline in Palisade’s stock at market open on 9 August, compared to market close on the previous day. The company’s market cap stands at $4.8m.

Recommended Reports

Preview

来源: Pharmaceutical Technology

ReportsLOA and PTSR Model - Rezvilutamide in Liver Failure (Hepatic Insufficiency) GlobalData

Preview

来源: Pharmaceutical Technology

ReportsLOA and PTSR Model - Aramchol in Liver Failure (Hepatic Insufficiency) GlobalData

View allCompanies IntelligencePalisade Bio, IncPalisade CorpView all

Tranexamic acid is a broad-spectrum serum protease inhibitorserum protease inhibitor. It reduces damage to the intestine by neutralising digestive enzymes.

The drug was investigated for the indication in a randomised, placebo-controlled, multicentre Phase II clinical trial (NCT02836470) that failed to meet its primary endpoint. Furthermore, 16 serious adverse events were observed in the tranexamic acid group, compared to 14 events in the placebo group, as per the press release.

The clinical trial was wrought with difficulties. It was paused in July 2020 due to Covid-19, leading to low patient recruitment. After its restart in May 2022, the study’s protocol was changed to investigate the use of LB1148 in reducing adhesions from its original indication of the return of gastrointestinal function in patients post-elective bowel resection surgery.

Tranexamic acid is also under development for post-operative ileus and accelerating the return of bowel function post-abdominal surgery.

PalisadePalisade has a development and licencing agreement with Newsora for the tranexamic acid programme in China. The agreement grants PalisadePalisade clinical, regulatory, and commercial milestone-based payments, as well as tiered royalty payments for net annual sales in greater China.

PalisadePalisade reduced its workforce by 30% at the start of 2023, as part of a cost-reduction strategy. As per the company’s 2022 financial report, it has cash reserves of $12.4m to fund its operation to mid-2024.

更多内容，请访问原始网站

文中所述内容并不反映新药情报库及其所属公司任何意见及观点，如有版权侵扰或错误之处，请及时联系我们，我们会在24小时内配合处理。